evipedia.ai
← Back

Oleoylethanolamide for Health & Longevity

Evidence Review created on 08/25/2026 using AI4L / Opus 5

Also known as: OEA, N-Oleoylethanolamide, N-Oleoylethanolamine, Oleoylethanolamine, Oleylethanolamide, cis-9-Octadecenoyl Ethanolamide

Motivation

Oleoylethanolamide is a fat-derived signaling molecule that the small intestine makes from oleic acid, the main fat in olive oil. Released after a fatty meal, it travels to the brain and helps produce the feeling of having eaten enough. Because it also switches on the cellular machinery that burns stored fat, it has drawn interest as a naturally occurring counterpart to appetite-suppressing medications — and it is now sold as an oral supplement.

The molecule was identified in the late 1990s and characterized in the early 2000s, when researchers found that giving it to animals reduced how much they ate and how much weight they gained. Human trials followed roughly fifteen years later, most of them small, most of them run by a handful of research groups in one country, and most of them in people carrying excess weight or fatty liver.

This review examines what the available human evidence shows about oleoylethanolamide’s effects on body composition, blood sugar, and inflammation; where that evidence is thin, conflicting, or shaped by who funded it; what is known about safety and dosing; and what the animal work on aging does and does not support.

Benefits - Risks - Protocol - Conclusion

Background reading on oleoylethanolamide (OEA) and its principal receptor PPAR-α (peroxisome proliferator-activated receptor alpha, a nuclear switch that turns on fat-burning genes), selected for depth rather than to reach a fixed count.

No content from any of the six priority platforms is listed because none has published an item that treats oleoylethanolamide in any depth. Life Extension is the only one that names the compound at all: once in a paragraph of a 2015 article about avocados, and once in a short subsection of a November 2020 article on four endocannabinoid-supporting compounds. Neither carries enough on oleoylethanolamide to qualify. Five qualifying sources were found, so the list is not padded, but note that four of the five are academic rather than the expert commentary this section usually favors.

Grokipedia

Oleoylethanolamide

A dedicated encyclopedic entry covering biosynthesis, receptor targets and the human trial record, useful mainly as a cross-check on receptor pharmacology and nomenclature.

Examine

Oleoylethanolamide

Notably more skeptical than the trial literature: it states there is currently no human evidence that oral OEA burns fat, and derives its dosing suggestion by scaling a rat dose to human body weight.

ConsumerLab

No dedicated ConsumerLab article, product review or quality test for oleoylethanolamide exists. The compound appears only inside ConsumerLab’s palmitoylethanolamide answer page, which is that site’s primary page for a different compound and therefore not a source for oleoylethanolamide product quality. No independent ConsumerLab testing of oleoylethanolamide products has been published.

Systematic Reviews

Systematic reviews and meta-analyses that pool the human and preclinical evidence on oleoylethanolamide and on the oleic acid it is made from.

The trade-off in this intervention is appetite suppression against nutritional adequacy, and the risk side is unrepresented: no systematic review or meta-analysis of oleoylethanolamide’s safety, tolerability or adverse-event profile has been published. Every listed review addresses the claimed benefit only.

Mechanism of Action

Oleoylethanolamide (OEA) is an N-acylethanolamine (a family of fat-derived signaling molecules) built in the small intestine from dietary oleic acid. Fat entering the enterocyte (intestinal lining cell) via the transporter CD36 is converted to N-oleoyl-phosphatidylethanolamine and then cleaved by NAPE-PLD (the enzyme that releases the finished signal) to yield OEA.

Its principal target is PPAR-α. Activation raises fatty-acid uptake, lipolysis (fat breakdown) and beta-oxidation (fat burning), and suppresses NF-κB (a master inflammatory switch). Two secondary targets are debated: GPR119 (a gut receptor), whose activation releases GLP-1 (glucagon-like peptide-1, the satiety and insulin hormone), and TRPV1 (the capsaicin-sensing ion channel) — described as an OEA agonist in some work, while a review of its metabolism reports it as an antagonist. A structural study added HIF-3α (an oxygen-sensing transcription factor) as a selective binding partner.

How the satiety signal reaches the brain is also contested. The classical account routes it through vagal sensory fibers; more recent experiments found intact OEA in brain tissue within minutes of dosing and eating inhibition even after the vagal route was cut, arguing for direct blood-borne access.

No human half-life has been published; rodent data indicate clearance on a scale of minutes. OEA is cleared by hydrolysis via FAAH and NAAA (the enzymes that break these lipids down), not by cytochrome P450 (the liver enzyme family that clears most drugs), and it does not bind the cannabinoid receptors CB1 or CB2.

Historical Context & Evolution

OEA was isolated from mammalian tissue in the 1990s as one of several N-acylethanolamines found alongside anandamide, the brain’s own cannabis-like compound. Its early identity was that of a chemical curiosity — structurally close to anandamide but silent at cannabinoid receptors, and therefore assumed to be a metabolic by-product rather than a signal in its own right.

That reading changed in 2003, when Daniele Piomelli’s group at the University of California, Irvine, reported that OEA levels in the small intestine rise on feeding and fall on fasting, and that giving OEA to rodents reduced meal size and body weight through PPAR-α. That finding placed OEA in the same receptor family as the fibrate lipid drugs and turned it from by-product into candidate.

Interest then split. Nutrition researchers pursued OEA as the mechanism linking olive-oil-rich diets to favorable body composition. Supplement manufacturers pursued it directly, and synthetic OEA capsules reached the market well before any human trial existed.

The first human randomized trials appeared in 2018, and the trial literature has since remained concentrated in a small cluster of Iranian academic centers, with industry-sponsored work appearing from 2025. Two things are worth holding open: the large weight losses seen in rodents have not been reproduced at human doses, and the metabolic and inflammatory signals that have partly held up rest on a narrow and geographically uniform evidence base rather than a settled one.

Expected Benefits

High 🟩 🟩 🟩

Reduced Body Fat, Waist Circumference and Body Weight

The most reliably replicated effect. A 2025 meta-analysis of ten randomized controlled trials found significant reductions in waist circumference, fat mass, body fat percentage, body mass index and body weight, with no loss of fat-free mass — the pattern a longevity-oriented user wants. Heterogeneity (variation between trials) was low for these outcomes and the authors graded certainty for fat mass and fat percentage as high. The effect was confined to participants obese at baseline and to doses of at least 250 mg daily; overweight and normal-weight subgroups showed nothing.

Magnitude: Pooled standardized mean difference (effect size expressed in standard-deviation units) −0.91, 95% CI (confidence interval, the range within which the true effect probably lies) −1.39 to −0.42 for waist circumference; −0.53 (−0.87 to −0.17) for fat mass; −0.46 (−0.80 to −0.11) for body fat percentage; −0.48 (−0.82 to −0.14) for body mass index; and −0.26 (−0.51 to −0.02) for body weight. Fat-free mass was unchanged at 0.01 (−0.32 to 0.35).

Lower Fasting Triglycerides

Triglycerides are the one blood lipid that moves consistently. Pooled across two trials the reduction was significant with zero heterogeneity, and the meta-analysis graded certainty as high — its top rating for any outcome. A separate trial in people with obesity reported the fall in absolute terms. Total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol were all unchanged, so this is triglyceride-specific rather than broad lipid improvement. Only two trials contributed, so the estimate rests on a narrow base.

Magnitude: Pooled standardized mean difference −0.45 (95% CI −0.79 to −0.10; p = 0.011, p being the probability of seeing an effect this large if the compound did nothing). In the trial reporting raw values, mean triglycerides fell from 166.3 to 142.2 mg/dL over eight weeks at 250 mg daily, a between-group difference that survived adjustment (p = 0.044).

Medium 🟩 🟩

Improved Fasting Glucose, Insulin and Insulin Resistance

Four trials — in prediabetes (blood sugar above normal but below the diabetes threshold), polycystic ovary syndrome and obesity with fatty liver — reported lower fasting glucose and insulin. Pooled effects were large, but heterogeneity exceeded 90%, publication bias (the skew left when null results go unpublished) appeared for the insulin-resistance index, and removing any of three contributing trials abolished that effect; certainty was graded low to very low. Hemoglobin A1c (the roughly three-month blood-sugar average) did not move, arguing the glucose shift may be short-lived rather than durable.

Magnitude: Pooled standardized mean difference −1.54 (95% CI −2.55 to −0.52) for fasting glucose, −2.03 (−3.40 to −0.66) for insulin and −5.46 (−10.07 to −0.85) for HOMA-IR (homeostatic model assessment of insulin resistance, a calculated index of how effectively insulin lowers blood sugar). Hemoglobin A1c was unchanged at −1.22 (−3.34 to 0.88). The glucose effect held only at doses of 250 mg daily or more.

Appetite Suppression and Reduced Energy Intake

In the largest appetite-specific trial, 250 mg daily for eight weeks reduced hunger, desire to eat and sweet craving and increased fullness on visual analog scales, alongside higher expression of the fat-burning receptor. A separate trial in the same population recorded a real fall in measured energy and carbohydrate intake, and an acute crossover study recorded smaller test meals after a single dose. The endpoint is subjective and the trials were small; whether the effect persists past twelve weeks is untested.

Magnitude: Measured carbohydrate intake fell from 422 to 368 g/day over eight weeks (p = 0.042), with a parallel drop in total energy intake (p = 0.035). Hunger, desire to eat, sweet craving and fullness all shifted significantly (all p < 0.01); the publications report significance without the visual-analog point estimates.

Improved Mood and Reduced Fatigue

A 2026 randomized, double-blind trial in 52 veterans with Gulf War Illness (a chronic multi-symptom condition affecting about a third of 1990–91 Gulf War veterans) gave 200 mg twice daily for ten weeks. Fatigue on the Multidimensional Fatigue Inventory and total mood disturbance on the Profile of Mood States both improved, as did self-reported energy, emotional well-being and social functioning. Cognitive performance and pain did not change. A single exploratory trial in a specific, mostly male, mostly older population; not replicated.

Magnitude: Fatigue and total-mood-disturbance scores each improved significantly versus placebo (p ≤ 0.05), together with three quality-of-life subscales, over ten weeks at 400 mg daily. The publication reports significance levels rather than point estimates, so the literature provides no outcome figure for these scales.

Improved Liver Enzymes in Fatty Liver Disease

In 76 people newly diagnosed with non-alcoholic fatty liver disease, 250 mg daily plus a calorie-restricted diet for twelve weeks lowered ALT and AST (alanine and aspartate aminotransferase, liver enzymes that leak into blood when liver cells are stressed) and raised high-density lipoprotein cholesterol against placebo. Liver-fat severity on ultrasound improved in both arms, the between-group difference falling just short of significance. Benefits were larger at higher starting body mass index. One trial, one center — not yet replicated.

Magnitude: ALT, AST, their ratio and triglycerides all fell significantly versus placebo while high-density lipoprotein cholesterol rose; liver-fat severity fell in both arms with a between-group p = 0.061. The publication reports direction and significance rather than absolute enzyme changes.

Low 🟩

Lower Inflammatory Markers ⚠️ Conflicted

Pooled data show falls in C-reactive protein (a general inflammation marker) and tumor necrosis factor alpha (a pro-inflammatory signaling protein) but not interleukin-6, certainty graded low. The best-conducted fatty-liver trial found no change. Net: present in some populations, absent in others.

Magnitude: Pooled standardized mean difference −0.82 (95% CI −1.53 to −0.11) for C-reactive protein and −1.15 (−1.94 to −0.35) for tumor necrosis factor alpha; interleukin-6 unchanged at −0.57 (−1.38 to 0.24). Both significant effects were confined to female-only trials and to doses below 250 mg daily; at 250 mg or above neither reached significance.

Reduced Menstrual Pain

In 44 young women with primary dysmenorrhea (painful periods with no underlying disease), 125 mg daily for two months lowered pain on a visual analog scale versus placebo. A later meta-analysis rated this trial at high overall risk of bias, and the finding stands alone.

Magnitude: Menstrual pain fell significantly versus placebo (p = 0.040) over 60 days at 125 mg daily, alongside falls in C-reactive protein and tumor necrosis factor alpha. The publication reports p-values without the visual-analog point scores, so the literature gives no absolute score change.

Speculative 🟨

Enhanced Post-Meal Incretin Hormone Response

A fixed-sequence, single-blind crossover study in 37 adults, funded by ingredient manufacturer Gencor Pacific, found 20–25% higher post-meal GLP-1 and GIP (glucose-dependent insulinotropic polypeptide, the other gut satiety hormone) after 300 mg. Unvalidated biomarkers.

Improved Oxidative-Stress Biomarkers

Pooled trials show large rises in total antioxidant capacity and falls in malondialdehyde (a marker of fat-oxidation damage). Both are unvalidated biomarkers, with 98% heterogeneity and detected publication bias.

Increased Akkermansia muciniphila Abundance

An eight-week trial in people with obesity found significantly more of this mucin-degrading gut bacterium at 250 mg daily. Abundance is an unvalidated surrogate; no clinical outcome was measured.

Neuroprotection in Neurodegeneration and Stroke Models

Mouse work reports reduced amyloid-beta pathology via PPAR-α and lysosomal gene programs, and rodent stroke models show smaller lesions. Basis is animal and cell work only; no human neurological outcome trial exists.

Longevity-Pathway Signaling ⚠️ Conflicted

In roundworms, OEA bound a lysosomal lipid chaperone and extended lifespan; another study found lowering these lipids mediates diet-restriction longevity. Invertebrate only. Net: worm data point both ways.

Benefit-Modifying Factors

  • FAAH C385A variant: The common C385A polymorphism in fatty acid amide hydrolase (the enzyme that degrades OEA) reduces enzyme activity and expression, per a review of the variant. Carriers should retain a given oral dose longer, though no trial has stratified by genotype.

  • PPAR-α promoter variants: Common variation in PPAR-α expression plausibly sets the ceiling on the fat-oxidation response. Trials measured PPAR-α messenger RNA as an outcome rather than as a stratifying variable, so this remains an inference from mechanism.

  • Baseline body mass index: The strongest known modifier. Pooled weight, body mass index and fasting-glucose effects reached significance only in participants who were obese at baseline; overweight and normal-weight subgroups showed nothing on those outcomes.

  • Baseline inflammatory and glycemic markers: Inverse to the above. C-reactive protein fell significantly only in the overweight subgroup, and glycemic gains were largest where fasting glucose or insulin resistance was already raised — headroom, not the compound, drives response size.

  • Sex: In subgroup analysis, C-reactive protein, tumor necrosis factor alpha, malondialdehyde and total antioxidant capacity moved significantly in female-only trials but not in mixed-sex trials. Dose and sex are confounded, since the female-only trials all used 125 mg.

  • Pre-existing fatty liver: The largest liver-enzyme and lipid gains appeared in people with diagnosed non-alcoholic fatty liver disease, and within that group scaled with starting body mass index. Metabolically healthy livers have no documented response.

  • Age: Trial participants averaged 20.6 to 69.2 years, but sustained dosing above age 50 rests on a single ten-week trial at mean age 59. Older adults with declining appetite may experience the satiety effect as a liability rather than a benefit.

  • Habitual oleic acid intake: Endogenous OEA is synthesized from dietary oleic acid, and high-oleic diets raise circulating levels. Someone already eating substantial olive oil starts from a higher baseline and plausibly has less to gain from a capsule.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse outcome has been recorded as a clinical endpoint or as a validated clinical surrogate in more than one trial — the published trials describe tolerability narratively rather than reporting graded adverse-event counts.

Medium 🟥 🟥

Unintended Reduction in Energy and Carbohydrate Intake

The mechanism that produces the benefit also produces the hazard. In an eight-week randomized trial in people with obesity, measured energy and carbohydrate intake both fell significantly at 250 mg daily — intended there, but unwanted for a lean, training, longevity-oriented user for whom adequate protein and total energy underpin muscle retention. Pooled data show fat-free mass unchanged over eight to twelve weeks, so beyond that window the concern is theoretical rather than demonstrated. Intake was captured by food diary, which under-reports.

Magnitude: Carbohydrate intake fell from 422 g/day (SD, standard deviation, the typical spread around the average: 103) to 368 g/day (SD 99) over eight weeks (p = 0.042), with total energy intake also significantly reduced (p = 0.035). Pooled fat-free mass was unchanged over the same horizon: standardized mean difference 0.01 (95% CI −0.32 to 0.35).

Low 🟥

Incompletely Characterized Tolerability and Absent Long-Term Safety Data

Mild gastrointestinal upset is the most commonly reported adverse effect; the longest trial ran fifteen weeks and reported no serious adverse events. No trial has published graded adverse-event tables, and nothing beyond about four months has been studied in humans.

Magnitude: Not quantified in available studies. No published trial reports adverse events as graded, numerator-over-denominator counts; tolerability is described narratively, so no incidence figure for gastrointestinal or any other symptom can be derived from the literature.

Inconsistent Effect on High-Density Lipoprotein Cholesterol ⚠️ Conflicted

One fatty-liver trial reported a rise, one three-day stroke trial reported a within-group fall, and the pooled estimate is null with 94% heterogeneity. Net: no reliable direction emerges for this lipid fraction.

Magnitude: Pooled standardized mean difference 0.51 (95% CI −0.94 to 1.95; p = 0.49) with 94% heterogeneity. Removing a single trial flips the pooled estimate to a significant increase of 1.24 (0.75 to 1.73) — the clearest demonstration of how unstable this outcome is.

Higher Endogenous Levels Track Worse Metabolic and Sleep States

Serum concentrations are roughly double in people with sleep apnea and rise in cerebrospinal fluid after sleep deprivation; in people with obesity the usual inverse relation with body mass index reverses. These are associations, and may reflect compensation rather than harm.

Magnitude: Serum OEA averaged 8.4 pmol/mL (95% CI 6.9–9.9) in patients with sleep apnea versus 4.0 (3.5–4.5) in controls after adjustment (p < 0.0001), and correlated with apnea severity (r² = 0.28, the share of one measure’s variation explained by the other; p = 0.02).

Speculative 🟨

Peroxisome Proliferation from Sustained PPAR-α Activation

Chronic PPAR-α agonism causes peroxisome proliferation and liver tumors in rodents. Humans express far less of this receptor in liver and are considered relatively resistant; no human data exist for oleoylethanolamide.

Locomotor Slowing and Malaise at High Doses

At 10 mg/kg injected, rats ate less but also moved less, and the authors concluded the appetite effect may be secondary to discomfort rather than true satiety. Rodent, injected, supraphysiological.

Raised Anandamide Tone Through Competition for FAAH

OEA and anandamide share the same degrading enzyme, so a large oral load could slow anandamide breakdown and raise cannabinoid-receptor signaling. Mechanistic inference only; no human study has measured this.

Risk-Modifying Factors

  • FAAH C385A variant: Reduced-function carriers clear both OEA and anandamide more slowly, which plausibly amplifies both the intended satiety effect and any competition-driven rise in anandamide tone. No trial has genotyped participants.

  • Baseline body mass index and lean mass: The lower the starting body mass index and the higher the training load, the more the appetite effect becomes a liability. Trials excluded lean participants, so this population is unstudied.

  • Baseline liver enzymes: Clearance depends on intestinal and hepatic amide hydrolases. Where ALT or AST is already substantially raised, handling of an oral load has not been characterized, and trials excluded significant liver disease.

  • Sex: All significant inflammatory and oxidative-stress effects arose in female-only trials, which also used the lowest dose. Whether women are genuinely more responsive, or simply better served by 125 mg, is unresolved.

  • Pre-existing eating disorders and sleep apnea: An appetite-suppressing agent opposes the therapeutic goal in restrictive eating disorders. In sleep apnea, endogenous levels are already about double, so added exogenous load enters an unstudied range.

  • Age: Only one sustained-dosing trial has enrolled a mean age above 50. Older adults already carry a higher baseline risk of age-related appetite loss and sarcopenia (loss of muscle mass and strength), which the compound’s primary action would compound.

Key Interactions & Contraindications

  • GLP-1 receptor agonists and dual incretin agonists (semaglutide, liraglutide, tirzepatide): Caution. Both suppress appetite and slow gastric emptying, so combining them risks additive nausea, early satiety and unintended undereating. Separating the two initiations by at least four weeks is the mitigating step.

  • Fibrates (fenofibrate, gemfibrozil, bezafibrate): Caution. Both act on PPAR-α; concurrent use duplicates receptor pressure with no documented added benefit. Monitoring triglycerides and liver enzymes rather than stacking, and changing only one agent at a time, are the mitigating steps.

  • Glucose-lowering drugs (metformin, sulfonylureas such as glimepiride and gliclazide, insulin): Monitor. Trials report lower fasting glucose and insulin resistance; added to a sulfonylurea or insulin this could push glucose lower. Weekly fasting-glucose checks through the first month are the mitigating step.

  • Orlistat (over-the-counter alli, prescription Xenical): Caution. Orlistat blocks intestinal fat digestion, cutting both the oleic acid available for endogenous synthesis and absorption of a fat-soluble supplement. Separating the doses by at least two hours is the mitigating step.

  • Common over-the-counter medicines (ibuprofen, naproxen, omeprazole, loperamide): No documented interaction. OEA is cleared by amide hydrolysis rather than cytochrome P450 enzymes, so the usual over-the-counter drug-metabolism conflicts do not apply. No mitigating action needed.

  • Palmitoylethanolamide: Caution. Both are broken down by fatty acid amide hydrolase, so taken together each slows the other’s clearance. Combined products therefore act as a higher effective dose, and a proportionate reduction is the mitigating step.

  • Supplements with additive metabolic effects (fish oil, conjugated linoleic acid, berberine, glucomannan): Monitor. Additive appetite and triglyceride effects are plausible but unstudied; the practical consequence is over-suppressed intake. Single-agent introduction alongside an energy-intake record is the mitigating step.

  • Anticoagulants and antiplatelet agents (warfarin, apixaban, high-dose fish oil): No documented interaction. No trial has reported bleeding events or clotting changes. No mitigating action beyond the monitoring those agents already require.

  • Calorie-restricted diets: Monitor. Every fatty-liver trial administered OEA alongside a calorie-restricted diet, so the reported benefits are additive to dieting rather than independent of it. Without the dietary change the published effect has no support.

  • Alcohol: Monitor. Heavy drinking depletes intestinal OEA and raises gut permeability; a Phase 2 trial is testing whether supplementation counteracts this. No dose adjustment is documented; the interaction is under study, not established.

Populations who should avoid Oleoylethanolamide:

  • Pregnant or breastfeeding women — no reproductive-toxicity data exist, and every published trial excluded pregnancy.
  • Anyone with a current or past restrictive eating disorder (anorexia nervosa, bulimia nervosa, avoidant/restrictive food intake disorder) or a body mass index below 18.5 kg/m².
  • Adults with unintentional weight loss exceeding 5% of body weight in six months, or diagnosed sarcopenia (appendicular lean mass index below 7.0 kg/m² in men, 5.5 kg/m² in women).
  • People with decompensated liver disease (Child-Pugh Class B or C) or an unexplained ALT above three times the upper limit of normal.
  • People with untreated moderate-to-severe obstructive sleep apnea (apnea–hypopnea index ≥ 15 events/hour), in whom endogenous levels are already roughly doubled.
  • Children and adolescents under 18, outside the single trial setting that studied primary menstrual pain.
  • Anyone with a known allergy to olive-derived or oleic-acid-derived ingredients.

Risk Mitigation Strategies

  • Two-week run-in at 125 mg once daily: the lowest trial dose. Mitigates mild gastrointestinal upset, the most commonly reported adverse effect, and reveals individual sensitivity before the 250 mg dose linked to weight and glucose effects.

  • Dosing with a fat-containing meal: OEA is a lipid and its physiological release is meal-triggered. Mitigates nausea and early satiety reported on an empty stomach, and aligns dosing with the substrate conditions under which it normally acts.

  • Weekly protein and total energy record for the first eight weeks: mitigates the documented fall in energy and carbohydrate intake, which averaged about 54 g/day of carbohydrate in trial participants and can pass unnoticed without a record.

  • A protein floor of 1.6 g/kg body weight daily: mitigates the muscle-retention risk created by unintended undereating, which matters more for a lean, training user than for the obese participants in whom the intake reduction was measured.

  • Four-weekly body-composition measurement rather than scale weight: mitigates unnoticed loss of lean tissue. Pooled fat-free mass was unchanged over eight to twelve weeks, but nothing beyond that window has been studied.

  • An eight-week recheck of ALT, AST and fasting glucose: mitigates unnoticed hepatic or glycemic drift, and matches the eight-week point at which pooled body-mass and inflammation effects first became significant.

  • A twelve-week cap on continuous use before formal reassessment: mitigates the complete absence of long-term safety data, since no human trial has run beyond about fifteen weeks.

  • Third-party-tested, single-ingredient product only: mitigates dose inaccuracy and adulteration, and makes any observed effect or adverse event attributable to OEA rather than to a stack.

Therapeutic Protocol

  • Standard dose: 250 mg daily is the most-used dose and the threshold at which pooled body-weight, body mass index and fasting-glucose effects reached significance. Trials span 125–600 mg/day.

  • Low-dose alternative: 125 mg daily is where pooled C-reactive protein, tumor necrosis factor alpha and oxidative-stress effects were significant, and where they vanished at 250 mg or above — an unexplained inverse dose relationship.

  • Best time of day: With or shortly before the largest fat-containing meal. Endogenous release is meal-triggered, and the acute incretin study dosed 15 minutes before a standardized meal.

  • Single versus split dosing: Both used. Two 125 mg capsules daily is the most common schedule; the Gulf War Illness trial used 200 mg twice daily. Splitting suits the short plasma residence.

  • Half-life: No human half-life is published. Rodent data indicate hydrolysis by FAAH and NAAA within minutes, which is the pharmacological argument for split rather than once-daily dosing.

  • Duration: Trials ran three days to fifteen weeks. Pooled body mass index and C-reactive protein effects required at least eight weeks; trials shorter than eight weeks showed neither.

  • Competing approach — dietary: Raising habitual oleic acid intake increases endogenous OEA. A systematic review of 28 feeding trials treats this as the food-based route to the same signal, with no capsule involved.

  • Competing approach — formulated ingredient: Branded dispersion-formulated OEA (Gencor Pacific’s TRPTI, using LipiSperse) is dosed at 150–300 mg. Its sponsor manufactures the ingredient, so the bioavailability claim rests on interested evidence.

  • Expert attribution: The pharmacological approach traces to Daniele Piomelli’s group at the University of California, Irvine; the human trial protocol traces to Alireza Ostadrahimi and Helda Tutunchi at Tabriz University of Medical Sciences.

  • Genetic polymorphisms: FAAH C385A carriers have reduced enzyme activity and should retain a dose longer, arguing for the 125 mg end. COMT (dopamine breakdown) and APOE4 (fat transport) show no documented relevance. No trial has genotyped participants.

  • Sex-based differences: Inflammatory and oxidative-stress responses reached significance only in female-only trials, all of which used 125 mg. Whether this reflects sex or dose cannot be separated from the published subgroups.

  • Age-related considerations: Only the ten-week Gulf War Illness trial dosed a cohort averaging above 50 years. For adults past 65, the appetite-suppressing action works against the higher baseline risk of age-related appetite loss and muscle wasting.

  • Baseline biomarkers: Response tracks headroom. Fasting glucose, insulin resistance, triglycerides, C-reactive protein and body mass index all predicted the size of the effect; participants starting near optimal showed no change.

  • Pre-existing conditions: Diagnosed fatty liver and prediabetes are the two conditions with the clearest documented response. Metabolically healthy participants have not been studied as a distinct group in any trial.

Discontinuation & Cycling

  • Lifelong versus short-term: No trial supports indefinite use. Every human study ran fifteen weeks or less, so use is best understood as a defined trial period with a measured endpoint, not an open-ended addition.

  • Withdrawal effects: None reported. No trial documented rebound overeating, weight regain during follow-up, or any withdrawal syndrome — though no trial included a post-treatment observation period long enough to detect one.

  • Tapering: Not applicable on current evidence. OEA is cleared within minutes and acts through a nuclear receptor with no documented tolerance or dependence, so abrupt cessation has no described consequence.

  • Cycling for efficacy: Not studied. Sustained high-fat feeding blunts the endogenous OEA satiety signal in animals, which is the only mechanistic argument for cycling; no human trial has tested on-off schedules.

  • Reassessment point: Twelve weeks. Body mass index and inflammatory effects require eight weeks to appear, so a shorter trial cannot rule out benefit and a longer one exceeds the studied safety window.

Sourcing and Quality

  • Synthetic origin: Commercial OEA is chemically synthesized by condensing oleic acid with ethanolamine, not extracted from olive oil. Labels implying an olive-oil extract describe the starting material, not the manufacturing route.

  • Purity and residual solvents: The synthesis leaves ethanolamine and free oleic acid as plausible residuals. A certificate of analysis showing purity above 98% by chromatography is the relevant specification, not merely a stated milligram content.

  • Formulation: OEA is poorly water-dispersible. Dispersion technologies such as LipiSperse (used in Gencor Pacific’s branded TRPTI) are marketed to improve uptake, but the comparative bioavailability data come from the manufacturer.

  • Third-party testing: No independent certification body has published OEA product testing, and ConsumerLab has never reviewed the category. NSF Certified for Sport or Informed Choice marks on the finished product are the practical substitute.

  • Dose per capsule: Trial doses were 125, 200, 250, 300, 400 and 600 mg. Products commonly supply 125 mg or 250 mg per capsule; matching the trial dose exactly is easier than splitting an odd unit.

  • Single-ingredient preference: OEA frequently appears inside proprietary fat-burner blends with stimulants. Single-ingredient product allows the dose to be known and any adverse effect to be attributed.

  • Compounding pharmacies: Not a relevant route. OEA is regulated as a dietary supplement rather than a drug in most jurisdictions, so it is sourced from supplement manufacturers rather than compounded.

Practical Considerations

  • Time to effect: Appetite and incretin changes appear within 15 minutes to hours of a single dose. Body mass index and inflammatory effects required at least eight weeks in pooled analysis; triglyceride and glucose shifts appeared by eight weeks.

  • Common pitfall — expecting drug-scale weight loss: The pooled body-weight effect is small, and the rodent results that generated interest have not reproduced at human doses. Examine’s own summary states there is no human evidence that oral OEA burns fat.

  • Common pitfall — omitting the dietary change: Every fatty-liver trial paired OEA with calorie restriction, so the published effects are additive to dieting. Taken alone, the intervention has never been shown to produce those results.

  • Common pitfall — assuming more is better: Inflammatory and oxidative-stress effects were significant below 250 mg and absent at or above it, while weight and glucose effects went the other way. Dose selection depends on the target.

  • Regulatory status: Sold as a dietary supplement in the United States and most other markets, with no approved therapeutic indication anywhere. It is not a prescription drug, so no prescribing information or regulator-reviewed safety label exists.

  • Cost and accessibility: Inexpensive and widely available online — typically a few tens of dollars for a two-to-three-month supply, and not a barrier to a self-funded trial.

  • Structural cost incentives: OEA competes conceptually with incretin weight drugs costing orders of magnitude more. Insurers and national health systems have a financial incentive to favor cheap supplements; drug manufacturers have the opposite — a bias shaping which comparison gets funded.

Interaction with Foundational Habits

  • Sleep: Bidirectional and mostly indirect. Sleep deprivation raises OEA in human cerebrospinal fluid, and rodents given OEA show increased waking and dopamine release. Levels are also about double in sleep apnea. Evening dosing has not been tested; taking the larger dose earlier in the day avoids the theoretical wake-promoting effect.

  • Nutrition: Direct and potentiating. Dietary oleic acid is the substrate for endogenous synthesis, so an olive-oil-rich diet raises baseline levels and a very low-fat diet suppresses them. Taking OEA with a fat-containing meal matches its physiological release; sustained high-fat feeding blunts the satiety signal in animals.

  • Exercise: Indirect, with no documented blunting. No trial has examined training outcomes, and pooled fat-free mass was unchanged over eight to twelve weeks, so no hypertrophy interference is evident. The practical concern is the appetite effect reducing the energy and protein intake that training requires.

  • Stress management: Indirect and plausibly potentiating. In a mouse model, OEA together with brain histamine reversed behavioral deficits from chronic social defeat stress, and the one human mood trial improved total mood disturbance and emotional well-being. No trial has measured cortisol or a stress-response endpoint.

Monitoring Protocol & Defining Success

Before starting, a baseline draw anchors every later comparison: fasting triglycerides, glucose, insulin, high-sensitivity C-reactive protein, ALT and AST, plus waist circumference and a body-composition scan. Baseline matters more than usual here, because the pooled trial effects on weight and fasting glucose appeared only in people who began with obesity, and the inflammatory effects only in those who began overweight — someone already lean has little documented headroom.

Ongoing testing follows a simple cadence: a repeat metabolic panel at 8 weeks, since the pooled analyses found body-mass and inflammation effects only in trials running 8 weeks or longer, then again at 6 months, then every 6–12 months if the compound is continued. Waist circumference and body composition are worth checking monthly, because they move earlier and more consistently than scale weight.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting triglycerides < 80 mg/dL (< 0.9 mmol/L) The blood lipid with the highest-certainty response 12-hour fast; conventional cut-off of < 150 mg/dL is far looser; pair with fasting insulin
Fasting glucose 75–86 mg/dL (4.2–4.8 mmol/L) Detects the glycemic shift seen in prediabetes and fatty-liver trials Conventional reference tops out at 99 mg/dL; morning draw after a 12-hour fast
Fasting insulin 2–5 µIU/mL More sensitive than glucose to early insulin resistance (reduced tissue response to insulin) Must come from the same fasted sample as glucose so HOMA-IR can be calculated
HOMA-IR < 1.0 Composite index of insulin resistance, the outcome with the largest pooled effect Calculated, not assayed: glucose × insulin ÷ 405 in mg/dL units; conventional threshold for resistance is 2.5
hs-CRP < 0.5 mg/L The inflammation marker with the largest pooled response hs-CRP is high-sensitivity C-reactive protein; repeat if infection or hard training preceded the draw; conventional “low risk” is < 1.0 mg/L
ALT and AST ALT < 20 U/L (women < 17 U/L); AST < 20 U/L Fatty-liver trials showed the clearest response here Conventional upper limits near 40 U/L miss early fatty liver; draw fasted and avoid intense exercise for 48 hours
Waist circumference < 94 cm men, < 80 cm women The body measurement with the largest pooled effect Measure at the iliac crest at end-expiration; more informative than scale weight for this compound
Body composition (fat mass, fat-free mass) No established target exists; track change from the individual’s own baseline, with fat mass falling and fat-free mass held flat Confirms that any weight change is fat rather than lean tissue DXA (dual-energy X-ray absorptiometry), or the same bioimpedance device at the same time of day and hydration state
Hemoglobin A1c 4.8–5.2% Shows whether short-term glucose shifts persist over three months Pooled trials found no effect, so a flat result is expected; unreliable with anemia or altered red-cell lifespan

Qualitative markers worth tracking alongside the labs:

  • Hunger, fullness and sweet craving, rated daily on a simple 0–10 scale — the endpoints that moved most clearly in the appetite trial.
  • Fatigue and general energy through the afternoon, the outcome that improved in the mood trial.
  • Mood stability and social engagement, which improved on validated scales in the same trial.
  • Digestive comfort in the first two weeks, since mild gastrointestinal upset is the most commonly reported adverse effect.
  • Whether protein and total food intake are being met without conscious effort, which is the earliest sign that appetite suppression has gone further than intended.

Emerging Research

  • Alcohol use disorder trial (NCT07503782): A 42-participant, triple-masked Phase 2 trial at the Medical University of South Carolina with the National Institute on Alcohol Abuse and Alcoholism, giving 250 mg daily for six weeks to adults aged 18–25, with peripheral interleukin-6, tumor necrosis factor alpha, interleukin-1 beta and lipopolysaccharide as primary endpoints.

  • Recruiting industry trials (NCT07315516, NCT07457723): Gencor Pacific is running two Phase 2 placebo-controlled trials of its branded formulation in Australia — 240 participants on sleep quality, stress and anxiety at 150 mg daily, and 90 on a gut metabolite linked to insulin resistance at 300 mg.

  • Industry epigenetic and metabolic study (NCT07127445): dōTERRA International, which sells the product, completed a 92-participant, 12-week study of a combination containing OEA, ginger extract and lavender oil, with genome-wide methylation and hemoglobin A1c as co-primary endpoints. Single-arm and unblinded, so the ingredient’s own contribution cannot be isolated.

  • Incretin mechanism study (NCT06840080): The completed 40-participant crossover study behind the 2026 incretin publication, run by a contract research organization for the ingredient manufacturer. Its acute, fixed-sequence, single-blind design makes it hypothesis-generating rather than confirmatory, and the results are now published in full.

  • Terminated satiety study (NCT03947281): The United States Department of Agriculture’s Western Human Nutrition Research Center trial, which tracked circulating OEA alongside other satiety hormones after snacks, was terminated with ten participants enrolled. Terminated and unpublished studies weaken the apparent consistency of the published record.

  • Replication outside a single country: Every trial in the Bahari et al., 2025 meta-analysis was conducted in Iran with overlapping investigators and the same capsule. Independent replication elsewhere is the one development most likely to move the evidence in either direction.

  • Lean and older adults: Pooled subgroup analyses in Bahari et al., 2025 found weight and fasting-glucose effects only in participants obese at baseline. Whether a lean, metabolically healthy adult gains anything — or loses appetite they cannot spare — has not been tested in any trial.

  • The invertebrate longevity contradiction: Folick et al., 2015 found OEA extends roundworm lifespan; Lucanic et al., 2011 found lowering the same lipid class mediates diet-restriction longevity. Neither has a mammalian follow-up, and resolving this would reshape how the compound is framed.

  • Neurodegeneration follow-through: Comerota et al., 2023, working in a mouse Alzheimer’s model, report reduced amyloid pathway burden via PPAR-α and lysosomal gene programs. No human neurological outcome trial has been registered, so this remains the largest gap between preclinical promise and clinical testing.

Conclusion

Oleoylethanolamide is a fat-derived signal the gut makes after a meal containing olive-oil-type fat, and the same molecule can be taken as a capsule. The human record is small but points one way: across about a dozen controlled trials, mostly short and mostly in people carrying extra weight or a fatty liver, it was linked to smaller waistlines, less body fat without loss of lean tissue, lower blood fats, and lower fasting blood sugar. Effects on inflammation markers were favorable on average but absent in some of the better-conducted work. Reported side effects have been limited to mild digestive upset — but no study has run longer than about four months, so years of use remain unexamined.

For someone already lean, metabolically healthy, and eating plenty of olive oil, the documented room to improve is narrow: the gains clustered in people who started heavier or with raised blood sugar, and the appetite-damping action is a liability rather than an asset for anyone whose priority is holding on to muscle.

Two features of the evidence base deserve weight. Almost every trial came from a small cluster of academic centers in one country using the same capsule, so nothing has been independently reproduced elsewhere; and the newest work comes from companies that sell the ingredient. The animal work on lifespan is genuinely split, one line finding that more of this molecule lengthens life in worms and another that less of it does.

Top - Benefits - Risks - Protocol